Dermatology co Foamix mulls Nasdaq IPO
Meir Heth: It's a shame the layoffs were not accompanied by an announcement of a 10% pay cut for directors and executives.
"The streamlining could have been carried in far wiser and more dignified way," former Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) chairman Prof. Meir Heth (81) told "Globes" in an interview. Heth is a small shareholder and part of Teva's founding core, which owns 10% of the company. "This was a public relations failure. It's a shame that the announcement of the layoffs was not accompanied by an announcement of a 10% pay cut for directors and executives. Had they been smart, they would have done that, and believe me, they could be reduced."
"Globes:" Do you think it reasonable for Teva to pay no taxes at all?
Heth: "No, but that was a conscious choice (by the Israeli government) and is not theft."
Teva sent director Chaim Hurvitz to placate the public.
"And he did not speak wisely. To say that Teva has to make cutbacks in order to pay taxes is not a smart thing to say."
For years, we heard almost nothing about layoffs at Teva
"Teva has fired many employees, especially overseas. There was never a strike; there was mutual respect. Teva established itself as a good place to work for employees and managers, and gave many benefits."
Teva-Tech employees are now on strike.
"This is not a pure strike. The man behind it is the secretary of the Beit She'an workers committee. He wants Teva to be managed by the committee. It's easy to do this now that Teva's image is poor. In the past, when there were threats of a strike, management announced that unless there were negotiations it would close the plant, and it's hard to close such a plant in which huge amounts were invested. If management surrenders now, it will lose its deterrence."
Are you upset that Teva is not as Israeli as it used to be?
"The company has become a multinational. It is run by two American Jews, chairman Phillip Frost and CEO Jeremy Levin. Do you know that Teva never sent Israelis to manage its foreign branches? It knew that Israelis would not understand the market like the locals. In the past, it was very important for Teva to preserve its Israeli character, but that's not happening now."
In response Teva stressed that Levin has Israeli citizenship.
In the past, you fought against Frost.
"Last year, some of the founders and I criticized the directors' exorbitant salaries, but the general shareholders meeting approved them. We felt it unbecoming, that this was a sign of Teva's loss of modesty."
Like financing Frost's private jet.
"Phillip Frost is a millionaire, a very successful businessman, the owner of Opko Health Inc. (NYSE: OPK; TASE: OPK), but he needs poor Teva to finance his cost of his private jet? Let him fly at his own expense, not at Teva's."
Heth is the great-grandson of Moshe Solomon, a scion of the family that founded Assia Chemical Industries, which was merged with Teva. He has served as supervisor of banks, chairman of the Tel Aviv Stock Exchange (TASE), chairman of Psagot Investment House Ltd., and chairman of Teva until 2002, when he was succeeded by the late Eli Hurvitz. He served on Teva's board of directors until 2009. He is currently a professor emeritus, specializing in business and financial law.
Published by Globes [online], Israel business news - www.globes-online.com - on October 24, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.